NYSE: WSTWest Pharmaceutical Services Inc Stock
$211.29-2.17 (-1.02%)
Updated Apr 30, 2025
WST Price
$211.29
Fair Value Price
N/A
Market Cap
$15.18B
52 Week Low
$187.43
52 Week High
$372.79
P/E
32.91x
P/B
5.66x
P/S
5.61x
PEG
6.04x
Dividend Yield
0.29%
Revenue
$2.90B
Earnings
$467.20M
Gross Margin
34.5%
Operating Margin
20.17%
Profit Margin
16.1%
Debt to Equity
0.35
Operating Cash Flow
$665M
Beta
0.87
Next Earnings
N/A
Ex-Dividend
Apr 30, 2025
Next Dividend
May 7, 2025
WST Overview
West Pharmaceutical Services Incorporated manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the U.S. and internationally. Its Proprietary Products segment offers stoppers and seals for injectable packaging systems, and syringe and cartridge components for injectable drug applications. The Contract-Manufactured Products segment manufactures and (automated) assembles devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical and medical device companies. The company was incorporated in 1923 and is headquartered in Exton, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WST's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
WST
Ranked#12 of 42
Ranked#12 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $65.68 | B | |
| $4.72 | B | |
| $207.09 | B |
Be the first to know about important WST news, forecast changes, insider trades & much more!
WST News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WST scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WST ($211.29) is trading above its intrinsic value of $48.70, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WST is poor value based on its earnings relative to its share price (32.91x), compared to the US market average (29.18x)
P/E vs Market Valuation
WST is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more WST due diligence checks available for Premium users.
Valuation
WST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
32.91x
Industry
40.62x
Market
29.18x
WST is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
WST is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
WST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.66x
Industry
3.73x
WST is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WST price to earnings growth (PEG)
For valuing profitable companies with growth potential
WST is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
WST's financial health
Profit margin
Revenue
$698.0M
Net Income
$89.8M
Profit Margin
12.9%
WST's Earnings (EBIT) of $584.20M... subscribe to Premium to read more.
Interest Coverage Financials
WST's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.6B
Liabilities
$935.1M
Debt to equity
0.35
WST's short-term assets ($1.46B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WST's short-term assets ($1.46B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WST's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$129.4M
Investing
-$71.3M
Financing
-$147.0M
WST's operating cash flow ($664.60M)... subscribe to Premium to read more.
Debt Coverage Financials
WST vs Medical Stocks
West Pharmaceutical Services Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.